The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
April 14, 2025
View Complete Issue         Table of Contents 2019 
Mirdametinib (Gomekli) for Neurofibromatosis Type 1 (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Mirdametinib (Gomekli) for Neurofibromatosis Type 1 (online only)
April 14, 2025 (Issue: 1726)
Mirdametinib (Gomekli – SpringWorks Therapeutics), an oral kinase inhibitor, has been approved by the FDA for treatment of neurofibromatosis type 1 (NF1) in patients ≥2 years old who have symptomatic plexiform neurofibromas not amenable to...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Mirdametinib (Gomekli) for Neurofibromatosis Type 1 (online only)
Article code: 1726g
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.